Compare Sterling Biotech with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs PROCTER & GAMBLE HEALTH - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH PROCTER & GAMBLE HEALTH STERLING BIOTECH/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x -0.4 53.0 - View Chart
P/BV x 0.0 4.6 0.3% View Chart
Dividend Yield % 0.0 10.3 -  

Financials

 STERLING BIOTECH   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
PROCTER & GAMBLE HEALTH
Dec-18
STERLING BIOTECH/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs113,549 0.3%   
Low Rs31,301 0.3%   
Sales per share (Unadj.) Rs26.8511.4 5.2%  
Earnings per share (Unadj.) Rs-15.061.3 -24.4%  
Cash flow per share (Unadj.) Rs-5.574.0 -7.4%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs54.9927.8 5.9%  
Shares outstanding (eoy) m267.8716.60 1,613.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.7 5.5%   
Avg P/E ratio x-0.539.6 -1.2%  
P/CF ratio (eoy) x-1.332.8 -3.9%  
Price / Book Value ratio x0.12.6 4.8%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m1,86240,257 4.6%   
No. of employees `0001.41.1 119.4%   
Total wages/salary Rs m5471,313 41.7%   
Avg. sales/employee Rs Th5,303.37,486.7 70.8%   
Avg. wages/employee Rs Th403.81,157.6 34.9%   
Avg. net profit/employee Rs Th-2,959.0897.2 -329.8%   
INCOME DATA
Net Sales Rs m7,1818,490 84.6%  
Other income Rs m43244 17.5%   
Total revenues Rs m7,2238,734 82.7%   
Gross profit Rs m9471,482 63.9%  
Depreciation Rs m2,543211 1,204.2%   
Interest Rs m4,3770-   
Profit before tax Rs m-5,9311,514 -391.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m-1,924563 -342.1%   
Profit after tax Rs m-4,0071,017 -393.8%  
Gross profit margin %13.217.5 75.6%  
Effective tax rate %32.437.1 87.3%   
Net profit margin %-55.812.0 -465.6%  
BALANCE SHEET DATA
Current assets Rs m14,33515,343 93.4%   
Current liabilities Rs m49,8091,960 2,541.0%   
Net working cap to sales %-494.0157.6 -313.4%  
Current ratio x0.37.8 3.7%  
Inventory Days Days40349 827.7%  
Debtors Days Days17128 599.8%  
Net fixed assets Rs m55,4321,209 4,583.8%   
Share capital Rs m268166 161.4%   
"Free" reserves Rs m13,93515,235 91.5%   
Net worth Rs m14,70115,401 95.5%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98817,595 420.5%  
Interest coverage x-0.4NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.5 20.1%   
Return on assets %0.55.8 8.7%  
Return on equity %-27.36.6 -412.5%  
Return on capital %-6.410.3 -62.6%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,8601,636 113.7%   
Fx outflow Rs m254,368 0.6%   
Net fx Rs m1,835-2,732 -67.2%   
CASH FLOW
From Operations Rs m1,719-1,304 -131.8%  
From Investments Rs m-3,14812,697 -24.8%  
From Financial Activity Rs m1,426-301 -474.5%  
Net Cashflow Rs m-311,093 -0.0%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.0 18.2 -  
FIIs % 9.9 1.0 990.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 29.1 135.1%  
Shareholders   21,482 28,591 75.1%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   SUVEN LIFESCIENCES  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - GSK PHARMA COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS